Rilzabrutinib
Especificaciones
1575591-66-0Número CAS
(E)-2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrileNombre IUPAC
C36H40FN9O3Fórmula química
665.8 g/molPeso molecular
Rilzabrutinib; PRN1008; PRN-1008; 1575591-66-0; (E)-2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile; Rilzabrutinib [INN]; Rilzabrutinib [USAN]; NWN58M4F5T; Example 31 [WO2014039899]; Example 31 (WO2014039899); (E/Z)-(R)-2-(3-(4-Amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enenitrile; 1-Piperidinepropanenitrile, 3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)-alpha-(2-methyl-2-(4-(3-oxetanyl)-1-piperazinyl)propylidene)-beta-oxo-, (alphaE/Z,3R)-; (E)-2-((3R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo(3,4-d)pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enenitrile; RefChem:883642; 1-PIPERIDINEPROPANENITRILE, 3-(4-AMINO-3-(2-FLUORO-4-PHENOXYPHENYL)-1H-PYRAZOLO(3,4-D)PYRIMIDIN-1-YL)-.ALPHA.-(2-METHYL-2-(4-(3-OXETANYL)-1-PIPERAZINYL)PROPYLIDENE)-.BETA.-OXO-, (.ALPHA.E/Z,3R)-; Rilzabrutinib, (E)-; (R,E)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enenitrile; 5G1WE425BI; PRN1008, (E)-; PRN-1008, (E)-; (R)-2-(3-(4-Amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enenitrile; Wayrilz; (2E)-2-{(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl}-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile; (alphaE,3R)-3-[4-Amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-alpha-[2-methyl-2-[4-(3-oxetanyl)-1-piperazinyl]propylidene]-beta-oxo-1-piperidinepropanenitrile; 2-((3R)-2-(4-Amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo(3,4-d)pyrimidin-1-yl)piperdine-1-carbonyl)-4-methyl-4(4-(oxetan-3-yl)piperazin-1-yl-(E)-pent-2-enenitrile; 2416219-30-0; Wayrilz (TN); (E)-RILZABRUTINIB; UNII-NWN58M4F5T; Rilzabrutinib [USAN:INN]; Rilzabrutinib (PRN1008); UNII-5G1WE425BI; Rilzabrutinib - API Standards; (.ALPHA.E,3S)-; GTPL9993; orb1309216; CHEMBL3702854; Rilzabrutinib (JAN/USAN/INN); SCHEMBL29368877; SCHEMBL29564512; C36H40FN9O3; Rilzabrutinib, (.alpha.e,3s)-; BDBM143212; (E)-PRN1008; EX-A4524; PRN 1008; BDBM50557485; EBC-64029; EBC-84050; NSC812901; PRN 1008?; WHO 10966; AKOS040735411; NSC-812901; Rilzabrutinib pound PRN1008 pound(c); NCGC00856431-01; (2E)-2-[(E)-(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile; AC-36557; DA-77069; FP167893; MS-31034; HY-112166; HY-151232; CS-0043590; D11873; D87222; T12542; EN300-1608336; EN300-7487650; US8940744, 31; Q50825085; (|AE,3R)-3-[4-Amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-|A-[2-methyl-2-[4-(3-oxetanyl)-1-piperazinyl]propylidene]-|A-oxo-1-piperidinepropanenitrile; (E)-2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile; 1-Piperidinepropanenitrile, 3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1Hpyrazolo(3,4-d)pyrimidin-1-yl)-alpha-(2-methyl-2-(4-(3-oxetanyl)-1-piperazinyl)propylidene)-beta-oxo-, (3R)-; 2-[(3R)-3-[3-(2-fluoro-4-phenoxyphenyl)-4-imino-1H,2H,4H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrileSinónimos